Results from the world’s first COVID-19 Characterisation Study Data shows SARS-CoV-2 human challenge studies are safe in healthy young adults
Open Orphan PLC (ORPH.L) World’s first COVID-19 Characterisation Study
Open Orphan PLC (ORPH.L) Malaria Human Challenge Model Launched
First volunteers inoculated with Malaria human challenge virus
Open Orphan PLC (ORPH.L) £5m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) $13.4m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a
Open Orphan PLC (ORPH.L) Positive results from Flu Human Challenge Study
Positive results from Influenza Human Challenge Study conducted by hVIVO
Open Orphan PLC (ORPH.L) Imutex Vaccine Phase I Study Results
mutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results
Open Orphan PLC (ORPH.L) £5.1m RSV Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) £1.5m Contract renewal for Venn Life Sciences
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan PLC (ORPH.L) Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment
How one company is testing vaccines through intentional infection
Open Orphan Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection.
Open Orphan PLC (ORPH.L) £5.7m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
